Patents Examined by Gregg Polansky
  • Methods of providing weight loss therapy in patients with major depression
    Patent number: 10322121
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 18, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Eduardo Dunayevich, Gary D. Tollefson
  • Therapeutically active compounds and their methods of use
    Patent number: 10294215
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 21, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Use of intravenous melatonin in patients with ST-elevation myocardial infarction
    Patent number: 10278956
    Abstract: The invention relates to a method of treating a subject who has suffered a myocardial infarction with ST-elevation and to a method of treating reperfusion injury in a subject, the method comprising intravenous administration of melatonin to the subject, wherein the administration is initiated within 3 hours or less of symptom onset and prior to the mechanical reperfusion and is maintained for at least 60 minutes.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 7, 2019
    Inventors: Alberto Domínguez Rodríguez, Pedro Abreu González
  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-? responses
    Patent number: 10273237
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: April 30, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, James Lin, Ryan M. Moslin, David S. Weinstein, John S. Tokarski
  • Pregabalin sustained-release preparation
    Patent number: 10258584
    Abstract: Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet contains a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing alginic acid, and a swellable material containing polyoxyethylene.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: April 16, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Jiajia Xu, Hao Chen
  • Cortexolone 17alpha-benzoate for use in the treatment of tumours
    Patent number: 10231980
    Abstract: The present invention provides certain cortexolone derivatives of formula (I), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: March 19, 2019
    Assignee: COSMO TECHNOLOGIES LTD.
    Inventor: Mara Gerloni
  • Copolymer and method for treatment of bacterial infection
    Patent number: 10226482
    Abstract: A method of treatment of infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: March 12, 2019
    Assignee: RECCE PHARMACEUTICALS LIMITED
    Inventors: Graham John Hamilton Melrose, Michele Keryn Dilizia
  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 10206933
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: February 19, 2019
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Methods and compositions for improving cognitive function
    Patent number: 10201522
    Abstract: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: February 12, 2019
    Assignee: MARS, INCORPORATED
    Inventors: Stephen French, Amar P Inamdar, Ian Andrew MacDonald, Susan T Francis
  • Methods for modulating the amount of RNA transcripts
    Patent number: 10195202
    Abstract: Described herein are methods for modulating the amount of a gene product and compounds for use in such methods. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product as the result of gene expression and compounds for use in such methods.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 5, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventor: Nikolai Naryshkin
  • Small molecules for endothelial cell activation
    Patent number: 10197557
    Abstract: The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: February 5, 2019
    Assignee: The Regents of the University of California
    Inventors: Daniel Cruz, Ohyun Kwon
  • Exo-S-mecamylamine formulation and use in treatment
    Patent number: 10188613
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: January 29, 2019
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Douglas Shytle, Paul R. Sanberg, Mary Newman, Archie A. Silver
  • Use of statins in the treatment of ischemic diseases
    Patent number: 10179121
    Abstract: The invention discloses statins compounds used as local intraosseous application for the treatment of ischemic diseases, in particular, discloses local intraosseous application of statin compounds in the treatment of peripheral ischemic diseases or cardio-cerebrovascular ischemic diseases.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: January 15, 2019
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Yingsheng Xu, Jie Tan, Qi Guo, Can Liu
  • Substituted pyrimidines useful as EGFR-T790M kinase inhibitors
    Patent number: 10167264
    Abstract: The present invention is directed to novel pyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases and/or mutants mediated diseases and conditions.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Jiangsu Medolution Ltd
    Inventor: Dawei Zhang
  • Compositions containing a bitter tastant and at least one sophorolipid, and methods of reducing bitter taste attributed to a bitter tastant in an edible composition
    Patent number: 10155043
    Abstract: A composition comprising a bitter tastant and at least one sophorolipid and optionally a carrier; wherein the composition is edible and wherein the bitter taste of said bitter tastant is reduced. A method of reducing bitter taste attributed to a bitter tastant in an edible composition, said method comprising adding to said edible composition an effective amount of at least one sophorolipid and optionally a carrier; such that any bitter taste induced by the bitter tastant is reduced.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: December 18, 2018
    Assignees: The United States of America, as Represented by the Secretary of Agriculture, Monell Chemical Senses Center
    Inventors: Daniel Solaiman, Richard D. Ashby, Mehmet Hakan Ozdener, Alexander Bachmanov
  • Composition containing essential oils and plant extracts for treating vaginal infection and inflammation
    Patent number: 10154958
    Abstract: A composition containing essential oils of two different species of Origanum, emulsified in water extracts of four herbs. The composition may be useful for prevention and/or treating major infections by pathogens such as Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans. When the composition is administered as a vaginal douche, rapid restoration of lactobacillus colony may occur after the administration.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 18, 2018
    Assignee: King Abdulaziz University
    Inventors: Taha Abdullah Kumosani, Elie Kamil Barbour, Werner Krull
  • Oxybutynin transdermal therapeutic system combination
    Patent number: 10149828
    Abstract: There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. In this combination, the acetylcholinesterase inhibitor (AChEI) is present at a dose that is higher than the maximal recommended dose, per unit form. In particular, the transdermal therapeutic system comprising oxybutynin is in combination with rivastigmine in a transdermal formulation or oral form.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: December 11, 2018
    Assignee: Chase Pharmaceuticals Corporation
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Ferrocenyl compounds
    Patent number: 10138261
    Abstract: A ferrocenyl compound having the general formula (I): (I) Het is a substituted or unsubstituted heterocyclic moiety. L1, L2 and L3 are each a linker independently selected from alkylene, alkyleneoxy, alkyleneoxyalkylene, alkylenecarbonyl, alkyleneoxycarbonyl, alkyleneamido, alkyleneoxyamido, alkenylene, alkenyleneoxy, alkenylenecarbonyl, alkenyleneamido, alkynylene, alkynyleneoxy, alkynylenecarbonyl and alkynyleneamido, all of which may be straight chain or branched, substituted or unsubstituted. R1 and R2 are each independently selected from H, substituted or unsubstituted alkyl carbonyl, substituted or unsubstituted aryl carbonyl, substituted or unsubstituted phosphate, substituted or unsubstituted phosphonate and substituted or unsubstituted phosphoramidate. M and n are each 0 or 1 and m+n?0.1.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignee: THE UNIVERSITY OF BIRMINGHAM EDGBASTON
    Inventors: Chris Tselepis, James Tucker, Huy Van Nguyen, Nikolas John Hodges, Youcef Mehellou
  • Compositions of vitamin D and methods for their use and manufacture
    Patent number: 10130641
    Abstract: The invention is directed to compositions of vitamin D having enhanced bioavailability and enhanced stability. Methods of making and using the compositions of the invention are contemplated and disclosed.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: November 20, 2018
    Inventors: Bruce L. Howe, Kodimule Shyam Prasad
  • Concentrated therapeutic phospholipid compositions
    Patent number: 10130644
    Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 20, 2018
    Assignee: ACASTI PHARMA INC.
    Inventors: Fotini Sampalis, Henri Harland